Legal Representation
Attorney
Timothy H. Hiebert
USPTO Deadlines 2 active 2 overdue
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
OFFICE ACTION
Non-Final Action E-Mailed |
GNRT | Nov 15, 2022 | 965 days overdue | Critical | Until Feb 15, 2023 |
|
OFFICE ACTION
Non-Final Action Mailed |
CNRT | Nov 15, 2022 | 965 days overdue | Critical | Until Feb 15, 2023 |
Application History
11 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 7, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Mar 7, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Mar 7, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Aug 15, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 15, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Aug 15, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 8, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Apr 10, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Apr 10, 2022 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Feb 18, 2022 | NWAP | I | NEW APPLICATION ENTERED |
| Feb 18, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations primarily comprising cells for the treatment of sickle cell disease; Pharmaceutical preparations primarily comprising cells for the treatment of beta thalassemia
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Providing medical and scientific research information in the field of blood disorders, and in the field of pharmaceuticals for treating blood disorders
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Providing health information to patients, caregivers and health care professionals; providing health care information relating to blood disorders, and information relating to the therapeutic properties of pharmaceuticals used for treating blood disorders
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
CTX ZERO ZERO ONE
Classification
International Classes
005
042
044